enabling drug discovery
Aptamers as Targeted Therapeutics
The ability of aptamers to specifically target a protein, protein domain, cell or tissue type etc is not only of interest for diagnostic developments; they are now being developed for their potential uses in therapeutics. There are several avenues for exploitation of aptamers as therapeutics; they may be used directly as therapeutic agents, form part of a therapeutic chimera, serve as a carrier for other therapeutic agents or be used to modulate their activity.
At Aptamer Therapeutics we specialise in the development of nucleic acid Aptamer Drug Conjugates (ApDCs) using our automated discovery platform.
The interest in this area is demonstrated by the number of scientific publications describing aptamers isolated against therapeutically relevant targets including examples associated with cardiovascular diseases, neurodegenerative diseases, to numerous viral targets including influenza, human immunodeficiency virus (HIV), hepatitis C virus (HCV) and herpes simplex virus (HSV), as well as a plethora of cancer associated targets.